CClinicalTrials.gg
CompletedNCT05380284SDSTUpdated Jun 1, 2023

Senior Driving Simulation Training for Subjective Cognitive Decline and Mild Cognitive Impairment

An interventional study of Senior Driving Simulation Training and Waiting list control in MCI, Subjective Cognitive Decline and Healthy Aging, sponsored by Taipei Medical University. Completed at 1 site in Taiwan. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-01.

Sponsored by Taipei Medical University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This study aims to establish the Senior Driving Simulation Training (SDST) for Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI), and explore the effectiveness of Senior Driving Simulation Training (SDST) on the executive function, cognitive function and EEG.

Read the detailed description

Driving behavior is a high cognitively demanding task, and whether the Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) can continue to drive is an important issue. This study will develop the Taiwan version of innovative, immediate feedback and environmentally safe Senior Driving Simulation Training (SDST). This study aims to establish the Senior Driving Simulation Training (SDST) for Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI), and explore the effectiveness of Senior Driving Simulation Training (SDST) on the executive function, cognitive function and EEG. The investigators intend to conduct a single-blind randomized controlled trial using a two-arm parallel-group design. Participants will be randomized by the permuted block randomization, block size of 4, into an experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) or a control group (Waiting list). The investigators plan to blind the therapists and outcome assessors to maintain the blinding methods' quality. The primary outcome indicators are mental set-shifting, working memory, and inhibition. The secondary outcome indicators are cognitive function and EEG. The investigators also evaluate visual awareness and simulator sickness. The short-term (immediate post-test) and the long-term (3, 6, and 12 months) effectiveness of the intervention on individual outcome measures will be analyzed by the generalized estimating equation. The investigators also plan to use the secondary data analysis methods to investigate the relationship between objective indicators of a driving simulator, executive function, cognitive function, EEG, visual awareness, and simulator sickness. Furthermore, the investigators will analyze the trend of EEG while the participants conducting the training, and complete the psychometric properties of the Chinese version of the Cognitive Change Index (C-CCI). This will be the first senior driving simulation training (SDST) for Subjective Cognitive Decline (SCD) and Mild Cognitive Impairment (MCI) in Taiwan. Results of the current study will provide valuable information on driving safety decisions and apply to promote the advanced driving policies.

02

Conditions studied

  • MCI
  • Subjective Cognitive Decline
  • Healthy Aging

Keywords

  • driving simulation
  • executive function
  • brain wave
03

In context

Cognitive Dysfunction

3,843 studies on the registry are indexed under Cognitive Dysfunction; 1,100 are open to participants now.

This study's enrollment of 90 is above the median of 65 across 2,808 interventional studies indexed under Cognitive Dysfunction.

Browse Cognitive Dysfunction studies →

Lead sponsor

Taipei Medical University is the lead sponsor of 245 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Subjective cognitive decline( AD-8 scale ≥1 point).
  • Mild cognitive impairment (AD-8 scale ≥ 2 points), and MMSE> 24 points, can maintain personal daily activity function.
  • Can communicate in Chinese or Taiwanese.
  • At least 60 years of age.
  • Those with a car driving license.
  • No physical impairment.
  • In addition to the above conditions, participants must be voluntary and signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • Dementia, diagnosed by a physician and in compliance with ICD-10.
  • Significant mental illness or communication impairment.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (actual)

Study arms

  • Experimental
    Experimental Group

    Senior Driving Simulation Training

    Other: Senior Driving Simulation Training

  • Other
    Control Group

    Waiting-list

    Other: Waiting list control

Interventions

  • OtherSenior Driving Simulation Training

    The experimental group (Senior Driving Simulation Training: 30-mins training session two times per week for 5 weeks, with a total of 10 sessions) .

  • OtherWaiting list control

    The control group is waiting list control. They will also receive the (Senior Driving Simulation Training) after all research is done.

06

What researchers measure

Primary outcomes

  1. Mental set shifting, measured by Wisconsin Card Sorting Test

    Mental set shifting is one of the sub-categories of executive function

    Time frame: immediate post-test

  2. Change from Baseline Mental set shifting, measured by Wisconsin Card Sorting Test at 3 months

    Mental set shifting is one of the sub-categories of executive function

    Time frame: 3 months follow-up

  3. Working memory, measured by Digit span test

    Working memory is one of the sub-categories of executive function

    Time frame: immediate post-test

  4. Change from Baseline Working memory, measured by Digit span test at 3 months

    Working memory is one of the sub-categories of executive function

    Time frame: 3 months follow-up

  5. Inhibition, measured by the Stroop Color and Word Test

    Inhibition is one of the sub-categories of executive function

    Time frame: immediate post-test

  6. Change from Baseline Inhibition, measured by the Stroop Color and Word Test at 3 months

    Inhibition is one of the sub-categories of executive function

    Time frame: 3 months follow-up

Secondary outcomes

  1. Cognitive function measured by Montreal Cognitive Assessment

    Cognitive function measured by Montreal Cognitive Assessment

    Time frame: immediate post-test

  2. Cognitive function measured by Cognitive Change Index(C-CCI)

    Cognitive function measured by Cognitive Change Index(C-CCI)

    Time frame: immediate post-test

  3. Change from Baseline cognitive function by Montreal Cognitive Assessment at 3 months

    Change from Baseline cognitive function by Montreal Cognitive Assessment at 3 months

    Time frame: 3 months follow-up

  4. Change from Baseline cognitive function by Cognitive Change Index(C-CCI)at 3 months

    Change from Baseline cognitive function by Cognitive Change Index(C-CCI)at 3 months

    Time frame: 3 months follow-up

  5. EEG

    EEG power in delta, theta, alpha, and beta band

    Time frame: immediate post-test

  6. Change from Baseline EEG at 3 months

    EEG power in delta, theta, alpha, and beta band

    Time frame: 3 months follow-up

  7. Visual awareness measured by CANTAB

    Visual awareness measured by CANTAB

    Time frame: immediate post-test

  8. Visual awareness measured by trail making test

    Visual awareness measured by trail making test

    Time frame: immediate post-test

  9. Change from Baseline visual awareness by CANTAB at 3 months

    Visual awareness measured by CANTAB

    Time frame: 3 months follow-up

  10. Change from Baseline visual awareness by trail making test at 3 months

    Change from Baseline visual awareness by trail making test at 3 months

    Time frame: 3 months follow-up

  11. simulator sickness

    Simulator Sickness Questionnaire (SSQ). The 16-item SSQ will be used to assess participants' sickness levels. This is the 4-point Likert scale (0 - "None" to 3 - "Severe"), and the higher total score reflects more severe sickness.

    Time frame: immediate post-test

  12. Usability

    The System Usability Scale (SUS) will be used to access the usability, this scale consists of 10 items, and the higher total score reflects better usability.

    Time frame: immediate post-test

  13. Acceptance

    The Technology Acceptance for Older Adults Scale will be used to access the acceptance, this scale consists of 17 items, and the higher total score reflects better acceptance.

    Time frame: immediate post-test

07

Study locations

1 site
  • Taipei Medical University
    Taipei, 110, Taiwan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05380284
Lead sponsor
Taipei Medical University
Responsible party
Huie-Ling Chiu (Assistant professor, Taipei Medical University) — Principal investigator
First posted
May 18, 2022
Start date
Jun 28, 2022
Primary completion
Jan 1, 2023
Completion
May 28, 2023
Last update
Jun 1, 2023

Study contacts

Huei-Ling Chiu
principal investigator · Taipei Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion